Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential

H.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.

Original reporting
Published Oct 6, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PHVS
Bullish
high confidence
Mentioned
$PHVS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PHVSBullishMed
01

Why it matters

Analyst upgrades and a new $60 target suggest the market may re‑price the stock higher, especially given the unmet need in acquired angioedema.

02

Market read

The trial data and analyst upgrades provide fresh, material information that could move PHVS price in the short term.

03

What to watch

Potential competition from other HAE therapies and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

Pharvaris (NASDAQ:PHVS) is developing an oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE). The CHAPTER-3 Phase 3 trial just reported strong efficacy results.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating with a $60 price target after positive Phase 3 trial data for deucrictibant in hereditary angioedema.

Expected impact

upside pressure as investors price in the trial success and higher price targets.

Evidence & confidence

The trial showed an 83% reduction in attack rates, prompting multiple analysts to raise targets, indicating strong upside potential.

Market effects

Positive data may boost sentiment in the rare‑disease biotech sector.

US biotech investors likely to respond positively.

Limited to pharma/biotech investors.

Counterpoint

If the drug faces regulatory hurdles or commercial uptake is slower than expected, the upside could be limited.

Key entities

  • Pharvaris B.V.

    Biotech firm developing deucrictibant for HAE.

  • H.C. Wainwright

    Reiterated Buy rating with $60 target.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.